Diabetes Treatment Revolution: Natco Pharma Launches Affordable Semaglutide in India

• Natco Pharma introduces generic Semaglutide injection in India, priced at Rs. 1,290 monthly, making it one of the cheapest GLP-1 diabetes therapies.
• Semaglutide, used for type 2 diabetes, will be available under brand names Semanat and Semafull in multi-dose vials, with a pen-device version coming in April.
• The launch follows the expiry of Semaglutide's patent in India, opening doors for lower-priced generics and ending Novo Nordisk's exclusive rights.
• Over 40 Indian companies, including Sun Pharma and Dr. Reddy's, plan to release 50+ generic versions, intensifying competition and further reducing prices.
• Natco's vial-based therapy is 70% cheaper than pen-devices and 90% cheaper than original brands, significantly increasing accessibility for millions of patients.